TELA Bio (TELA) Projected to Release Quarterly Earnings on Monday

TELA Bio (NASDAQ:TELA) will likely be issuing its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect TELA Bio to announce earnings of ($0.17) per share and revenue of $20.0080 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

TELA Bio (NASDAQ:TELA) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.07). TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 49.30%.The firm had revenue of $19.06 million for the quarter, compared to analyst estimates of $18.60 million. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

TELA Bio Stock Up 2.1%

NASDAQ TELA opened at $0.72 on Monday. TELA Bio has a fifty-two week low of $0.50 and a fifty-two week high of $2.14. The business has a fifty day moving average price of $0.80 and a two-hundred day moving average price of $0.81. The company has a debt-to-equity ratio of 8.82, a current ratio of 3.61 and a quick ratio of 2.92. The stock has a market capitalization of $32.46 million, a PE ratio of -0.92 and a beta of 1.34.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, TELA Bio currently has an average rating of “Hold” and an average target price of $2.20.

Hedge Funds Weigh In On TELA Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in shares of TELA Bio during the fourth quarter worth $48,000. Citadel Advisors LLC lifted its holdings in TELA Bio by 161.3% during the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after buying an additional 21,781 shares during the period. Susquehanna International Group LLP lifted its holdings in TELA Bio by 551.2% during the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after buying an additional 72,594 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of TELA Bio by 101.4% in the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after buying an additional 64,800 shares during the last quarter. 94.35% of the stock is currently owned by institutional investors and hedge funds.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial?stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.